Therapeutic strategies in HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP)

Central Nervous System Agents in Medicinal Chemistry

Volumn 9, Issue 2, 2009, Pages 137-149

  Nakamura, Tatsufumi ^a   Nishiura, Yoshihiro ^a   Eguchi, Katsumi ^a  

^a NAGASAKI UNIVERSITY   (Japan)

Author keywords

HAM TSP; HTLV I; Treatment

Indexed keywords

ALLICIN; ALPHA INTERFERON; APOPTOSIS SIGNAL REGULATING KINASE 1; ASCORBIC ACID; BETA1A INTERFERON; BUTYRIC ACID; DACLIZUMAB; ERYTHROMYCIN; FOSFOMYCIN; HEPARIN; IMMUNOGLOBULIN; LAMIVUDINE; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; PENTOXIFYLLINE; PREDNISOLONE; PROBIOTIC AGENT; PROSULTIAMINE; THIAMINE; TRICHOSTATIN A; UNCLASSIFIED DRUG; VALPROIC ACID; ZIDOVUDINE;

ABSENCE OF SIDE EFFECTS; ANTIVIRAL ACTIVITY; APOPTOSIS; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; COMPETITIVE INHIBITION; CORTICOSTEROID THERAPY; CYTAPHERESIS; DISEASE ASSOCIATION; DRUG DOSE ESCALATION; DRUG MEGADOSE; DRUG STRUCTURE; FERMENTED PRODUCT; GASTRODUODENAL ULCER; GLUCOSE INTOLERANCE; HUMAN; HUMAN T CELL LEUKEMIA VIRUS 1; HUMAN T CELL LEUKEMIA VIRUS INFECTION; HYPERTENSION; IMMUNOMODULATION; IMMUNOPATHOGENESIS; INFECTION; LACTOBACILLUS CASEI; LONG TERM CARE; MILK; MYOPATHY; NONHUMAN; OSTEOPOROSIS; PLASMAPHERESIS; REVIEW; SIGNAL TRANSDUCTION; SPASTIC PARAPLEGIA; SPINAL CORD DISEASE; TREATMENT DURATION;

AFRICA; BRONCHOALVEOLAR LAVAGE FLUID; CARIBBEAN REGION; CARRIER STATE; CELL COUNT; CELL LINE; DIAGNOSIS, DIFFERENTIAL; DNA, VIRAL; HTLV-I INFECTIONS; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMANS; INTERFERON-GAMMA; JAPAN; LEUKOCYTES, MONONUCLEAR; MIDDLE EAST; PARAPARESIS, TROPICAL SPASTIC; SOUTH AMERICA; SPINAL CORD; SPINAL CORD DISEASES; TH1 CELLS;

EID: 67049114116     PISSN: 18715249     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152409788452090     Document Type: Review

References (87)

1. Yoshida, M. Multiple viral strategies of HTLV-1 for dysregulation of cell growth control. Annu. Rev. Immunol., 2001, 19, 475-496. (Pubitemid 32368043)
2. Osame, M.; Usuku, K.; Izumo, S.; Ijichi, N.; Amitani, H.; Igata, A.; Matsumoto, M.; Tara, M. HTLV-I associated myelopathy, a new clinical entity. Lancet, 1986, 1, 1031-1032. (Pubitemid 16102987)
3. de Thé, G.; Bomford, R. An HTLV-I vaccine: why, how, for whom? AIDS Res. Hum. Retroviruses , 1993, 9, 381-386.
4. Hollsberg, P.; Hafler D.A. Pathogenesis of diseases induced by human T-lymphotropic virus type I infection. N. Engl. J. Med., 1993, 328, 1173-1182.
5. Osame, M.; Matsumoto, M.; Usuku, K.; Izumo, S.; Ijichi, N.; Amitani, H.; Tara, M.; Igata, A. Chronic progressive myelopathy associated with elevated antibodies to human T-lymphotropic virus type I and adult T-cell leukemia-like cells. Ann. Neurol., 1987, 21, 117-122. (Pubitemid 17016827)
6. Iwasaki, Y. Pathology of chronic myelopathy associated with HTLV-I infection (HAM/TSP). J. Neurol. Sci., 1990, 96, 103-123. (Pubitemid 20137633)
7. Ijichi, S.; Izumo, S.; Eiraku, N.; Machigashira, K.; Kubota, R.; Nagai, M.; Ikegami, N.; Kashio, N.; Umehara, F.; Maruyama, I.; Osame, M. An autoaggressive process against bystander tissues in HTLV-I-infected individuals: a possible pathomechanism of HAM/TSP. Med. Hypotheses, 1993, 41, 542-547. (Pubitemid 24049614)
8. Osame, M. Pathological mechanisms of human T-cell lymphotropic virus type I-associated myelopathy (HAM/TSP). J. Neurovirol., 2002, 8, 359-364. (Pubitemid 35446706)
9. Jeffery, K.J.; Usuku, K.; Hall, S.E.; Matsumoto, W.; Taylor, G.P.; Procter, J.; Bunce, M.; Ogg G.S.; Welsh, K.I.; Weber, J.N.; Lloyd, A.L.; Nowak, M.A.; Nagai, M.; Kodama, D.; Izumo, S.; Osame, M.; Bangham, C.R. HLA alleles determine human T-lymphotropic virus-I (HTLV-I) proviral load and the risk of HTLV-I-associated myelopathy. Proc. Natl. Acad. Sci. USA, 1999, 96, 3848-3853. (Pubitemid 29168999)
10. Nagai, M.; Usuku, K.; Matsumoto, W.; Kodama, D.; Takenouchi, N.; Moritoyo, T.; Hashiguchi, S.; Ichinose, M.; Bangham, C.RM.; Izumo, S.; Osame, M. Analysis of HTLV-I proviral load in 202 HAM/TSP patients and 243 asymptomatic HTLV-I carriers: high proviral load strongly predisposes to HAM/TSP. J. Neurovirol., 1998, 4, 586-593. (Pubitemid 29042065)
11. Nakamura, T. Immunopathogenesis of HTLV-I-associated myelopatrhy/tropical spastic paraparesis. Ann. Med., 2000, 32, 600-607. (Pubitemid 32115817)
12. Bangham, C.R.M.; Osame, M. Cellular immune response to HTLV-I. Oncogene, 2005, 24, 6035-6046.
13. Nakamura, T.; Nishiura, Y.; Fukushima, N.; Furuya, T. In Neuroimmunology Research Focus, Broglio P.V.; Ed.; Nova Science Publishers: New York, 2007, pp. 43-84.
14. Nakagawa, M.; Nakahara, K.; Maruyama, Y.; Kawabata, M.; Higuchi, I.; Kubota, H.; Izumo, S.; Arimura, K.; Osame, M. Therapeutic trials in 200 patients with HTLV-I-associated myelopathy/tropical spastic paraparesis. J. Neurovirol., 1996, 2, 345-355. (Pubitemid 26372460)
15. Kira, J.; Fujihara, K.; Itoyama, Y.; Goto, I.; Hasuo, K. Leukoencephalopathy in HTLV-I-associated myelopathy/tropical spastic paraparesis: MRI analysis and a 2 year follow-up study after corticosteroid therapy. J. Neurol. Sci., 1991, 106, 41-49.
16. Gesaain, A.; Gout, O. Chronic myelopathy associated with human T-lymphotropic virus type I (HTLV-I). Ann. Intern. Med., 1992, 117, 933946.
17. Matsuzaki, T.; Nakagawa, M.; Nagai, M.; Usuku, K.; Higuchi, I.; Arimura, K.; Kubota, H.; Izumo, S.; Akiba, S.; Osame, M. HTLV-I proviral load correlates with progression of motor disability in HAM/TSP: analysis of 239 HAM/TSP patients including 64 patients followed up for 10 years. J. Neurovirol., 2001, 7, 228-234. (Pubitemid 32685257)
18. Matsuo, H.; Nakamura, T.; Tsujihata, M.; Kinoshita, I.; Satoh, A.; Tomita, I.; Shirabe, S.; Shibayama, K.; Nagataki, S. Plasmapheresis in treatment of human T-lymphotropic virus type-I associated myelopathy. Lancet, 1988, ii, 1109-1113. (Pubitemid 18255748)
19. Ward, A.; Clissold, S.P. Pentoxifylline: a review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drug, 1987, 34, 50-97. (Pubitemid 17092322)
20. Panettieri, Jr., R.A.; Lazaar, A.L.; Puré, E.; Albelda, S.M. Activation of cAMP-dependent pathways in human airway smooth muscle cells inhibits TNF-α-induced ICAM-1 and VCAM-1 expression and lymphocyte adhesion. J. Immunol., 1995, 154, 2358-2365.
21. Tsujino, A.; Nakamura, T.; Nishiura, Y.; Shirabe, S.; Furuya, T.; Goto, H.; Kawakami, A.; Eguchi, K.; Nagataki, S. Pentoxifylline down-regulates adhesion molecule expression and inflammatory cytokine production in cultured peripheral blood mononuclear cells from patients with HTLV-I-associated myelopathy. J. Neuroimmunol., 1997, 73, 191-196. (Pubitemid 27105286)
22. Shirabe, S.; Nakamura, T.; Tsujino, A.; Nishiura, Y.; Furuya, T.; Goto, H.; Suenaga, A.; Nakane, S.; Yoshimura, T.; Nagataki, S. Successful application of pentoxifylline in the treatment of HTLV-I associated myelopathy. J. Neurol. Sci., 1997, 151, 97-101. (Pubitemid 27398017)
23. Itoyama, Y.; Minato, S.; Kira, J.; Goto, I.; Sato, H.; Okochi, K.; Yamamoto, N. Spontaneous proliferation of peripheral blood lymphocytes increased in patients with HTLV-I-associated myelopathy. Neurology, 1988, 38, 1302-1307. (Pubitemid 18218622)
24. Fujimoto, T.; Nakamura, T.; Furuya, T.; Nakane, S.; Shirabe, S.; Kambara, C.; Hamasaki, S.; Yoshimura, T.; Eguchi, K. Relationship between the clinical efficacy of pentoxifylline treatment and elevation of serum T helper type 2 cytokine levels in patients with human T-lymphotropic virus type I-associated myelopathy. Intern. Med., 1999, 38, 717-721. (Pubitemid 29436750)
25. Nakamura, T.; Furuya, T.; Nishiura, Y.; Ichinose, K.; Shirabe, S.; Eguchi, K. Importance of immune deviation toward Th1 in the early immunopathogenesis of human T-lymphotropic virus type I-associated myelopathy. Med. Hypotheses, 2000, 54, 777-782. (Pubitemid 30326507)
26. Izumo, S.; Usuku, K.; Osame, M.; Machigashira, K.; Johnosono, M.; Nakagawa, M. In HTLV-I and the nervous system; Roman, G.C.; Vernant, J-C.; Osame, M.; Eds.; Alan R Liss: New York, 1989, pp. 261-267.
27. Weiner, H.L.; Hafler, D.A. Immunotherapy of multiple sclerosis. Ann. Neurol., 1988, 23, 211-222.
28. Willenborg, D.; Parish, C. Inhibition of allergic encephalomyelitis by sulphated polysaccharides (abstracvt). J. Neuroimmunol., 1987, 16, 182183.
29. Nagasato, K.; Nakamura, T.; Ichinose, K.; Nishiura, Y.; Ohishi, K.; Shibayama, K.; Watanabe, H.; Tsujihata, M.; Nagataki, S. Heparin treatment in patients with human T-lymphotropic virus type I (HTLV-I)-associated myelopathy: a preliminary study. J. Neurol. Sci., 1993, 115, 161-168. (Pubitemid 23102444)
30. Nimmerjahn, F.; Ravetch, J.V. Anti-inflammatory actions of intravenous immunoglobulin. Annu. Rev. Immunol., 2008, 26, 513-533.
31. Kuroda, Y.; Takashima, H.; Ikeda, A.; Endo, C.; Neshige, R.; Kakigi, R.; Shibasaki, H. Treatment of HTLV-I-associated myelopathy with high-dose intravenous gammaglobulin. J. Neurol., 1991, 238, 309-314.
32. Kataoka, A.; Imai, H.; Inayoshi, S.; Tsuda, T. Intermittent high-dose vitamin C therapy in patients with HTLV-I associated myelopathy. J. Neurol. Neurosurg. Psychiatr., 1993, 56, 1213-1216. (Pubitemid 23323662)
33. Sugimoto, M.; Matsumoto, M.; Imamura, F.; Nakashima, H.; Uyama, E.; Araki, S. Effects of erythromycin on lymphocyte function in patients with HTLV-I-associated myelopathy. Jpn. J. Inflammation, 1990, 10, 387-391.
34. Yamano, Y.; Machigashira, K.; Ijichi, S.; Usuku, K.; Kawabata, M.; Arimura, K.; Osame, M. Alteration of cytokine levels by fos-fomycin and prednisolone in spontaneous proliferation of cultured lymphocytes from patients with HTLV-I-associated myelopathy (HAM/TSP). J. Neurol. Sci., 1997, 151, 163-167. (Pubitemid 27421847)
35. Amsden, G.W. Anti-inflammatory effects of macrolides - an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions? J. Antimicrob. Chemother., 2005, 55,10-21. (Pubitemid 40192609)
36. Alvarez-Olmos, M.I.; Oberhelman, R.A. Probiotic agents and infectious diseases: a modern perspective on a traditional therapy. Clin. Infect. Dis., 2001, 32, 1567-1576. (Pubitemid 32458724)
37. Matsuzaki, T.; Saito, M.; Usuku, K.; Nose, H.; Izumo, S.; Arimura, K.; Osame, M. A prospective uncontrolled trial of fermented milk drink containing viable Lactobacillus casei strain Shirota in the treatment of HTLV-I associated myelopathy/tropical spastic paraparesis. J. Neurol. Sci., 2005, 237, 75-81. (Pubitemid 41384017)
38. Fujihara, K.; Itoyama, Y.; Yu, F.; Kubo, C.; Goto, I. Cellular immune surveillance against HTLV-I infected T lymphocytes in HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP). J. Neurol. Sci., 1991, 105, 99-107.
39. Yu, F.; Itoyama, Y.; Fujihara, K.; Goto, I. Natural killer (NK) cells in HTLV-I-associated myelopathy/tropical spastic paraparesis-decrease in NK cell subset populations and activity in HTLV-I seropositive individuals. J. Neuroimmunol., 1991, 33, 121-128.
40. Vannucchi, S.; Chiantore, M.V.; Mangino, G.; Percario, Z.A.; Affabris, E.; Fiorucci, G.; Romeo, G. Perspectives in biomolecular therapeutic intervention in cancer: from the early to the new strategies with type I interferons. Curr. Med. Chem., 2007, 14, 667-679. (Pubitemid 46477719)
41. Kovarik, P.; Sauer, I.; Schaljo, B. Molecular mechanisms of the anti-inflammatory functions of interferons. Immunobiology, 2008, 212, 895-901. (Pubitemid 350246265)
42. Borden, E.C.; Sen, G.C.; Uze, G.; Silverman, R.H.; Ransohoff, R.M.; Foster, G.R.; Stark, G.R. Interferons at age 50: past, current and future impact on biomedicine. Nat. Rev. Drug Discov., 2007, 6, 975-990. (Pubitemid 350201788)
43. Izumo, S.; Goto, I.; Itoyama, Y.; Okajima, T.; Watanabe, S.; Kuroda, Y.; Araki, S.; Mori, M.; Nagataki, S.; Matsukura, S.; Akamine, T.; Nakagawa, M.; Yamamoto, I.; Osame, M. Interferon-alpha is effective in HTLV-I-associated myelopathy: a multicenter, randomized, double-blind, controlled trial. Neurology, 1996, 46, 1016-1021. (Pubitemid 26134644)
44. Shibayama, K.; Nakamura, T.; Nagasato, K.; Shirabe, S.; Tsujihata, M.; Nagataki, S. Interferon-alpha treatment in HTLV-I-associated myelopathy: studies of clinical and immunological aspects. J. Neurol. Sci., 1991, 106, 186-192.
45. Azimi, N.; Jacobson, S.; Leist, T.; Waldmann, T.A. Involvement of IL-15 in the pathogenesis of human T lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis: implications for therapy with a monoclonal antibody directed to the IL-2/IL-15Rβ receptor. J. Immunol., 1999, 163, 4064-4072. (Pubitemid 29450938)
46. Jacobson, S. Immunopathogenesis of human T cell lymphotropic virus type I-associated neurologic disease. J. Infect. Dis., 2002, 186(Suppl 2), S187-192. (Pubitemid 35370480)
47. + cells in patients with HTLV-I-associated myelopathy/tropical spastic paraparesis: correlation with HTLV-I provirus load. J. Infect. Dis., 2001, 183,197-205.
48. Yamano, Y.; Nagai, M.; Brennan, M.; Mora, C.A.; Soldan, S.S.; Tomaru, U.; Takenouchi, N.; Izumo, S.; Osame, M.; Jacobson, S. Correlation of human T-cell lymphotropic virus type 1 (HTLV-1) mRNA with proviral DNA load, virus-specific CD8+ T cells, and disease severity in HTLV-1-associated myelopathy (HAM/TSP). Blood, 2002, 99, 88-184
49. Saito, M.; Nakagawa, M.; Kaseda, S.; Matsuzaki, T.; Jonosono, M.; Eiraku, N.; Kubota, R.; Takenouchi, N.; Nagai, M.; Furukawa, Y.; Usuku, K.; Izumo, S.; Osame, M. Decreased human T lymphotropic virus type I (HTLV-I) provirus load and alteration in T cell phenotype after interferon-α therapy for HTLV-I-associated myelopathy/tropical spastic paraparesis. J. Infect. Dis., 2004, 189, 29-40. (Pubitemid 38122326)
50. Feng, J.; Misu, T.; Fujihara, K.; Misawa, N.; Koyanagi, Y.; Shiga, Y.; Takeda, A.; Sato, S.; Takase, S.; Kohnosu, T.; Saito, H.; Itoyama, Y. Th1/Th2 balance and HTLV-I proviral load in HAM/TSP patients treated with interferon-α. J. Neuroimmunol., 2004, 151, 189-194. (Pubitemid 38624413)
51. Oh, U.; Yamano, Y.; Mora, C.A.; Ohayon, J.; Bagnato, F.; Butman, J.A.; Dambrosia, J.; Leist, T.P.; McFarland, H.; Jacobson, S. Interferon-β1a therapy in human T-lymphotropic virus type I-associated neurologic disease. Ann. Neurol., 2005, 57, 526-534. (Pubitemid 40471162)
52. Bermel, R.A.; Rudick, R.A. Interferon-beta treatment for multiple sclerosis. Neurotherapeutics, 2007, 4, 633-646.
53. Asquith, B.; Mosley, A.J.; Heaps, A.; Tanaka, Y.; Taylor, G.P.; McLean, A.R.; Bangham, C.R. Quantification of the virus-host interaction in human T lymphotropic virus I infection. Retrovirology, 2005, 2, 75. (Pubitemid 41829869)
54. Wattel, E.; Vartanian, J.P.; Pannetier, C.; Wain-Hobson, S. Clonal expansion of human T-cell leukemia virus type I-infected cells in asymptomatic and symptomatic carriers without malignancy. J. Virol., 1995, 69, 2863-2868.
55. Cavrois, M.; Leclercq, I.; Gout, O.; Gessain, A.; Wain-Hobson, S.; Wattel, E. Persistent oligoclonal expansion of human T-cell leukemia virus type I-infected circulating cells in patients with tropical spastic paraparesis/HTLV-1 associated myelopathy. Oncogene, 1998, 17, 77-82. (Pubitemid 28360531)
56. Matsushita, S.; Mitsuya, H.; Reitz, M.S.; Broder, S. Pharmacological inhibition of in vitro infectivity of human T lymphotropic virus type 1. J. Clin. Invest., 1987, 80, 394-400.
57. Gout, O.; Gessain, A.; Iba-Zizen, M.; Kouzan, S.; Bolgert, F.; de The, G.; Lyon-Caen, O. The effect of zidovudine on chronic myelopathy associated with HTLV-1. J. Neurol., 1991, 238, 108-109.
58. Sheremata, W.A.; Benedict, B.S.; Squilacote, D.C.; Sazant, A.; DeFreitas, E. High-dose zidovudine induction in HTLV-I-associated myelopathy: safety and possible efficacy. Neurology, 1993, 43, 2125-2129. (Pubitemid 23318891)
59. Taylor, G.P.; Hall, S.E.; Navarrete, S.; Michie C.A.; Davis, R.; Witkover, A.D.; Rossor, M.; Nowak, M.A.; Rudge, P.; Matutes, E.; Bangham, C.R.M.; Weber, J.N. Effect of lamivudine on human T-cell leukemia virus type 1 (HTLV-1) DNA copy number, T-cell phenotype, and anti-tax cytotoxic T-cell frequency in patients with HTLV-1-associated myelopathy. J. Virol., 1999, 73, 10289-10295.
60. Taylor, G.P.; Goon, P.; Furukawa, Y.; Green, H.; Barfield, A.; Mosley, A.; Nose, H.; Babiker, A.; Rudge, P.; Usuku, K.; Osame, M.; Bangham, C.R.M.; Weber, J.N. Zidovudine plus lamivudine in human T-lymphotropic virus type-I-associated myelopathy: a randomized trial. Retrovirology, 2006, 3, 63. (Pubitemid 44541907)
61. Inoue, J.; Seiki, M.; Taniguchi, T,; Tsuru, S.; Yoshida, M. Induction of interleukin 2 receptor gene expression by p40x encoded by human T cell leukemia virus type I. EMBO J., 1986, 5, 2883-2888.
62. Tendler, C.L.; Greenberg, S.L.; Blattner, W.A.; Manns, A.; Murphy, E.; Fleisher, T.; Hanchard, B.; Morgan, O.; Burton, J.D.; Nelson, D.L.; Waldmann, T.A. Transactivation of interleukin 2 and its receptor induces immune activation in human T lymphotropic virus type I-associated myelopathy: pathological implications and a rationale for immunotherapy. Proc. Natl. Acad. Sci. USA, 1990, 87, 5218-5222. (Pubitemid 20224304)
63. Waldmann, T.A. Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey. J. Clin. Immunol., 2007, 27, 1-18. (Pubitemid 46224930)
64. Lehky, T.J.; Levin, M.C.; Kubota, R.; Bamford, R.N.; Flerlage, A.N.; Soldan, S.S.; Leist, T.P.; Xavier, A.; White, J.D.; Brown, M.; Fleisher, T.A.; Top, L.E.; Light, S.; McFarland, H.F.; Waldmann, T.A.; Jacobson, S. Reduction in HTLV-I proviral load and spontaneous lymphoproliferation in HTLV-I-associated myelopathy/tropical spastic paraparesis patients treated with humanized anti-Tac. Ann. Neurol., 1998, 44, 942-947. (Pubitemid 28558256)
65. Carey, N.; La Thangue, N.B. Histone deacetylase inhibitors: gathering pace. Curr. Opin. Pharmacol., 2006, 6, 369-375. (Pubitemid 44040838)
66. Abel, T.; Zukin, R.S. Epigenetic targets of HDAC inhibition in neurodegenerative and psychiatric disorders. Curr. Opin. Pharmacol., 2008, 8, 57-64.
67. Ego, T.; Ariumi, Y.; Shimotohno, K. The interaction of HTLV-I tax with HDAC1 negatively regulates the viral gene expression. Oncogene, 2002, 21, 7241-7246. (Pubitemid 35305612)
68. Lu, H.; Pise-Masison, C.A.; Linton, R.; Park, H.U.; Schiltz, R.L.; Sartorelli, V.; Brady, J.N. Tax relieves transcriptional repression by promoting histone deacetylase 1 release from the human T-cell leukemia virus type 1 long terminal repeat. J. Virol., 2004, 78, 6735-6743. (Pubitemid 38781510)
69. Lezin, A.; Gillet, N.; Olindo, S.; Signaté, A.; Grandvaux, N.; Verlaeten, O.; Belrose, G.; Bittencourt, M.C.; Hiscott, J.; Asquith, B.; Burny, A.; Smadja, D.; Césaire, R.; Willems, L. Histone deacetylase- mediated transcriptional activation reduces proviral loads in HTLV-1-associated myelopathy/tropical spastic paraparesis. Blood, 2007, 110, 3722-3728. (Pubitemid 350159642)
70. + cell antiviral function in HTLV-1 infection. Blood, 2006, 108, 3801-3807.
71. Ankri, S.; Mirelman, D. Antimicrobial properties of allicin from garlic. Microbes. Infect., 1999, 2, 125-129.
72. Hirsch, K.; Danilenko, M.; Giat, J.; Miron, T.; Rabinkov, A.; Wilchek, M.; Mirelman. D.; Levy, J.; Sharoni, Y. Effect of purified allicin, the major ingredient of freshly crushed garlic, on cancer cell proliferation. Nutr. Cancer, 2000, 38, 245-254. (Pubitemid 32762025)
73. Wong, W.W.; Macdonald, S.; Langler, R.F.; Penn, L.Z. Novel synthetic organosulfur compounds induce apoptosis of human leukemic cells. Anticancer Res., 2000, 20, 1367-1374. (Pubitemid 30628139)
74. Lawson, L.D.; Wang, Z.J. Pre-hepatic fate of the organosulfur compounds derived from garlic (Allium sativum). Planta Med., 1993, 59(Suppl.), 688-689. (Pubitemid 24023268)
75. Freeman, F.; Kodera, Y. Garlic chemistry - stability of S-(2-propenyl) 2-propene-1-sulfinothioate (allicin) in blood, solvents, and simulated physiological fluids. J. Agric. Food Chem., 1995, 43, 2332-2338.
76. Fujiwara, M.; Watanabe, H.; Matsui, K. "Allithiamine" a newly found derivative of vitamin B1. I. discovery of allithiamine. J. Biochem., 1954, 41, 29-39.
77. Matsukawa, T.; Yurugi, S. On the structure of allithiamine. Proc. Jpn. Acad., 1952, 28, 146-149.
78. Matsutani, H.; Ueda, S.; Yodoi, J. The thioredoxin system in retroviral infection and apoptosis. Cell Death Differ., 2005, 12, 991-998. (Pubitemid 41030612)
79. Lillig, C.H.; Holmgren, A. Thioredoxin and related molecules-from biology to health and disease. Antioxid. Redox Signal., 2007, 9, 25-47. (Pubitemid 44901873)
80. Teshigawara, K.; Maeda, M.; Nishino, K.; Nikaido, T.; Uchiyama, T.: Tsudo, M.; Wano, Y.; Yodoi, J. Adult T cell leukemia cells produce a lymphokine that augments interleukin 2 receptor expression. J. Mol. Cell. Immunol., 1985, 2, 17-26.
81. Tagaya, Y.; Maeda, Y.; Mitsui, A.; Kondo, N.; Matsui, H.; Hamuro, J.; Brown, N.; Arai, K.; Yokota, T.; Wakasugi, H.; Yodoi, J. ATL-derived factor (ADF), an IL-2 receptor/Tac inducer homologous to thioredoxin; possible involvement of dithiol-reduction in the IL-2 receptor induction. EMBO J., 1989, 8, 757-764. (Pubitemid 19273247)
82. Nakamura, H.; Nakamura, K.; Yodoi, J. Redox regulation of cellular activation. Annu. Rev. Immunol., 1997, 15, 351-369. (Pubitemid 27169285)
83. Ichijo, H.; Nishida, E.; Irie, K.; Ten Dijke, P.; Saitoh, M.; Moriguchi, T.; Takagi, M.; Matsumoto, K.; Miyazono, K.; Gotoh, Y. Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways. Science, 1997, 275, 90-94. (Pubitemid 27020316)
84. Hayakawa, T.; Matsuzawa, A.; Noguchi, T.; Takeda, K.; Ichijo, H. The ASK1-MAP kinase pathways in immune and stress responses. Microbes Infect., 2006, 8, 1098-1107.
85. Saitoh, M.; Nishitoh, H.; Fujii, M.; Takeda, K.; Tobiume, K.; Sawada, Y.; Kawabata, M.; Miyazono, K.; Ichijo, H. Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J., 1998, 17, 2596-2606. (Pubitemid 28221195)
86. Tobiume, K.; Saitoh, M.; Ichijo, H. Activation of apoptosis signal-regulating kinase 1 by the stress-induced activating phosphorylation of pre-formed oligomer. J. Cell. Physiol., 2002, 191, 95-104. (Pubitemid 34195221)
87. Blattacharyya, A.; Pathak, S.; Basak, C.; Law, S.; Kundu, M.; Basu, J. Execution of macrophage apoptosis by mycobacterium avium through apoptosis signal-regulating kinase 1/p38 mitogen-activated protein kinase signaling and caspase 8 activation. J. Biol. Chem., 2003, 278, 26517-26525. (Pubitemid 36876794)